Anti-hCD19 CAR IVT mRNA
VectorBuilder’s anti-hCD19 CAR IVT mRNA encodes a CAR protein consisting of an scFv targeting human CD19, a CD8 transmembrane domain, and a co-stimulatory domain (CD28 or 4-1BB) fused to CD3 zeta. The anti-hCD19-hBBz design has been shown to induce robust immune activation with lower levels of cytokine release and higher expression of anti-apoptotic proteins when compared to other CARs. The mRNA products are capped with Cap1, contain validated 5’ and 3’ UTRs, and have a 110 nt polyA tail.
Ordering Information Price Match
Click here to view the amino acid sequence translated from Anti-hCD19-h28z CAR IVT mRNA >>
Click here to view the amino acid sequence translated from Anti-hCD19-hBBz CAR IVT mRNA >>
Shipping and storage
Our IVT mRNA products are stored in a 1 mM sodium citrate buffer (pH 6.4) and can be stored at -80°C for up to 12 months. RNA products are shipped on dry ice and freeze-thaw cycles should be avoided.
Experimental Validation
- Anti-hCD19-h28z CAR IVT mRNA
- Anti-hCD19-hBBz CAR IVT mRNA
Figure 1. Expression of Anti-hCD19-h28z CAR IVT mRNA in HEK293T cells. (A) Design of Anti-hCD19-h28z CAR IVT mRNA. (B) CAR expression in HEK293T cells 24 hours post-transfection detected by Western blot using anti-CD3 zeta antibody. Non-specific bands indicated by (*).
Figure 1. Validation of Anti-hCD19-hBBz CAR IVT mRNA in HEK293T cells. (A) Design of Anti-hCD19-hBBz CAR mRNA. (B) CD19 stimulation of HEK293T cells expressing CAR IVT mRNA. HEK293T cells were transfected with Anti-hCD19-hBBz CAR mRNA with or without N1-Methylpseudouridine (m1Ψ). At 24 h post transfection, cells were incubated with PE-labeled human CD19 and analyzed by FACS. (C) CAR expression in HEK293T cells was validated by Western blot using anti-CD3 zeta antibody.
Resources
Documents
Brochures & Flyers
Certificate of Analysis (COA)
Material Safety Data Sheet (MSDS)